DNA — Ginkgo Bioworks Holdings, Inc. stock price, charts and financials
QT33Ginkgo Bioworks Holdings, Inc.Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -5.37 | Insider Own | - | Shs Outstand | 65.32M | Perf Week | 21.69% |
| Market Cap | 612.09M | Forward P/E | - | EPS next Y | -3.18 | Insider Trans | -0.34% | Shs Float | 47.85M | Perf Month | -7.32% |
| Enterprise Value | 650.09M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 10.88% | Perf Quarter | -5.45% |
| Income | -305.00M | P/S | 4.34 | EPS this Y | 29.89% | Inst Trans | - | Short Ratio | 4.17 | Perf Half Y | 2.29% |
| Sales | 141.00M | P/B | 1.38 | EPS next Y | 15.41% | ROA | -29.46% | Short Interest | 5.21M | Perf YTD | 12.76% |
| Book/sh | 6.78 | P/C | 1.64 | EPS next 5Y | - | ROE | -57.31% | 52W High | 17.58 -46.70% | Perf Year | -23.13% |
| Cash/sh | 5.71 | P/FCF | - | EPS past 3/5Y | - | ROIC | -31.12% | 52W Low | 5.37 74.49% | Perf 3Y | -90.40% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -29.15% 17.16% | Gross Margin | 74.97% | Volatility | 7.37% 6.54% | Perf 5Y | -97.63% |
| Dividend TTM | - | EV/Sales | 4.61 | EPS Y/Y TTM | 49.05% | Oper. Margin | -210.66% | ATR (14) | 0.61 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.15 | Sales Y/Y TTM | -37.89% | Profit Margin | -215.41% | RSI (14) | 60.35 | Recom | 2.91 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.15 | EPS Q/Q | 12.03% | SMA20 | 12.22% | Beta | 1.76 | Target Price | 7.84 |
| Payout | 0.00% | Debt/Eq | 0.82 | Sales Q/Q | -60.42% | SMA50 | 6.93% | Rel Volume | 0.91 | Prev Close | 8.94 |
| Employees | 485 | LT Debt/Eq | 0.82 | Earnings | Aug 06 | SMA200 | 6.61% | Avg Volume | 1.17M | Price | 9.37 |
| IPO Date | Apr 19, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -14.77% -54.64% | Net Debt/EBITDA | -1.27 | Volume | 1,064,590 | Change | 4.81% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-25-25 | Reiterated | BTIG | Sell | $7.00 → $9.00 |
| Aug-23-24 | Reiterated | BTIG | Sell | $6.00 → $7.00 |
| May-15-24 | Downgrade | BTIG | Neutral → Sell | |
| May-10-24 | Downgrade | William Blair | Market Perform → Underperform | |
| Nov-15-23 | Downgrade | Raymond James | Outperform → Market Perform | |
| Nov-14-23 | Downgrade | Raymond James | Outperform → Market Perform | |
| Nov-09-23 | Downgrade | BTIG | Buy → Neutral | |
| Jun-02-23 | Downgrade | Goldman Sachs | Neutral → Sell | |
| May-11-23 | Downgrade | William Blair | Outperform → Market Perform | |
| Nov-29-22 | Initiated | Berenberg Bank | $6.00 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 141 | 170 | 227 | 251 | 478 | 314 | 77 | 54 | |
| Cost of Goods Sold Incl. D&A | 36 | 32 | 39 | 54 | 204 | 130 | 16 | 0 | |
| Gross Profit | 107 | 139 | 188 | 197 | 273 | 184 | 61 | 54 | |
| Selling, General and Administrative Excl. Other | 172 | 183 | 246 | 385 | 1,430 | 863 | 38 | 29 | |
| Research and Development | 222 | 244 | 424 | 581 | 1,053 | 1,150 | 160 | 96 | |
| Other Operating Expense | 9 | 27 | 78 | 96 | -1 | 0 | 0 | 1 | |
| Operating Income | -298 | -315 | -560 | -864 | -2,209 | -1,828 | -137 | -72 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -2 | 2 | 12 | -28 | 88 | -7 | 15 | -46 | |
| Net Income Before Taxes | -299 | -314 | -548 | -893 | -2,121 | -1,838 | -125 | -120 | |
| Income Taxes | -1 | -1 | 0 | 0 | -15 | -1 | 2 | 0 | |
| Consolidated Net Income | -305 | -313 | -547 | -893 | -2,105 | -1,830 | -127 | -119 | |
| Net Income From Continuing Operations | -298 | -313 | -547 | -893 | -2,106 | -1,837 | -127 | -120 | |
| Net Income | -305 | -313 | -547 | -893 | -2,105 | -1,830 | -127 | -119 | |
| EPS (Recurring) | -5.37 | -5.64 | -10.54 | -18.37 | -50.15 | -53.83 | -3.97 | -4.15 | |
| EPS (Basic, Before Extraordinaries) | -5.37 | -5.64 | -10.54 | -18.37 | -50.15 | -53.83 | -3.97 | -4.15 | |
| EPS (Diluted) | -5.37 | -5.64 | -10.54 | -18.40 | -50.20 | -55.53 | -4.00 | -4.15 | |
| EBITDA | -211 | -255 | -484 | -821 | -2,060 | -1,807 | -109 | -107 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.99 | 2.69 | 2.25 | 13.20 | 5.94 | 34.93 | — | — | |
| Gross Margin | 75.89 | 81.76 | 82.82 | 78.49 | 57.11 | 58.60 | 79.22 | 100.00 | |
| Operating Margin | -211.35 | -185.29 | -246.70 | -344.22 | -462.13 | -582.17 | -177.92 | -133.33 | |
| Net Margin | -216.31 | -184.12 | -240.97 | -355.78 | -440.38 | -582.80 | -164.94 | -220.37 | |
| Shares Outstanding | 60 | 55 | 52 | 49 | 42 | 33 | 32 | 29 | |
| Market Capitalization | 562 | 457 | 511 | 3,312 | 2,839 | 10,969 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Coen Steven P. | See remarks | Jul 17 '26 | Sale | 7.90 | 752 | 5,943 | 51,438 | Jul 20 |
| Coen Steven P. | See remarks | Jul 16 '26 | Option Exercise | 0.00 | 1,486 | 0 | 52,190 | Jul 20 |
| Coen Steven P. | See remarks | May 22 '26 | Sale | 8.33 | 307 | 2,559 | 50,704 | May 26 |
| Coen Steven P. | See remarks | May 21 '26 | Option Exercise | 0.00 | 743 | 0 | 51,011 | May 26 |
| Coen Steven P. | See remarks | Apr 17 '26 | Sale | 7.95 | 324 | 2,576 | 50,268 | Apr 20 |
| Coen Steven P. | See remarks | Apr 16 '26 | Option Exercise | 0.00 | 743 | 0 | 50,592 | Apr 20 |
| Coen Steven P. | See remarks | Apr 13 '26 | Sale | 6.41 | 33,171 | 212,759 | 49,849 | Apr 14 |
| Coen Steven P. | See remarks | Apr 10 '26 | Option Exercise | 0.00 | 73,921 | 0 | 83,020 | Apr 14 |
| Canton Barry | 10% Owner | Apr 10 '26 | Sale | 6.43 | 124,727 | 802,494 | 436,422 | Apr 13 |
| Shetty Reshma P. | See remarks | Apr 10 '26 | Sale | 6.43 | 124,727 | 802,494 | 436,422 | Apr 13 |
| Shetty Reshma P. | See remarks | Apr 09 '26 | Option Exercise | 0.00 | 251,786 | 0 | 561,149 | Apr 13 |
| Canton Barry | 10% Owner | Apr 09 '26 | Option Exercise | 0.00 | 251,786 | 0 | 561,149 | Apr 13 |
| Canton Barry | 10% Owner | Apr 09 '26 | Sale | 6.40 | 13,116 | 83,903 | 338,568 | Apr 10 |
| Shetty Reshma P. | See remarks | Apr 09 '26 | Sale | 6.40 | 13,116 | 83,903 | 338,568 | Apr 10 |
| Kelly Jason R | See remarks | Apr 09 '26 | Sale | 6.40 | 109,767 | 702,179 | 316,483 | Apr 10 |